Sam Brusco, Associate Editor04.11.23
Implanet, a company specializing in vertebral implants and distribution of technological medical equipment, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Squale anterior cervical cage.
The Squale anterior cervical cage has a range of implants with design that was adapted to vertebral anatomy. The implants are radiolucent to facilitate radiographic confirmation of interbody fusion. Implanet gained the Squale cage from its March 2021 acquisition of a majority stake in Orthopaedic Spine & Development (OSD).
According to Implanet, to date over 15,000 Squale cages have been implanted globally. FDA clearance of Squale follows the first U.S. surgeries in 2022 using the ORIGIN cervical plate. This marked the first collaboration between Implanet and OSD.
Implanet CEO Ludovic Lastennet told the press: "This new clearance demonstrates once again the full potential of the synergies offered by the range of products in the OSD portfolio and is fully in line with our strategy to revitalize our presence in the United States. The Implanet America sales teams should be able to launch the marketing of this anterior cervical cage range before the summer of 2023. This is a new step for our development plan in the United States, aimed in particular at strengthening our offer in the field of spinal surgery in a market estimated at $1.35 billion1.”
Reference
1 Source Global Market Model 2018
The Squale anterior cervical cage has a range of implants with design that was adapted to vertebral anatomy. The implants are radiolucent to facilitate radiographic confirmation of interbody fusion. Implanet gained the Squale cage from its March 2021 acquisition of a majority stake in Orthopaedic Spine & Development (OSD).
According to Implanet, to date over 15,000 Squale cages have been implanted globally. FDA clearance of Squale follows the first U.S. surgeries in 2022 using the ORIGIN cervical plate. This marked the first collaboration between Implanet and OSD.
Implanet CEO Ludovic Lastennet told the press: "This new clearance demonstrates once again the full potential of the synergies offered by the range of products in the OSD portfolio and is fully in line with our strategy to revitalize our presence in the United States. The Implanet America sales teams should be able to launch the marketing of this anterior cervical cage range before the summer of 2023. This is a new step for our development plan in the United States, aimed in particular at strengthening our offer in the field of spinal surgery in a market estimated at $1.35 billion1.”
Reference
1 Source Global Market Model 2018